Clinicaltrials.gov identifier:
NCT04379999 (https://clinicaltrials.gov/show/NCT04379999)
Prevention
Study Contact Information:
Contact: Yana Chertock, MA by phone: 215-214-3216 or by email
This study will look at how well atorvastatin (a common cholesterol lowering agent) works with or without aspirin in preventing colorectal cancer in people with Lynch syndrome. Atorvastatin may lower the risk of developing cancers in the colon and rectum. Aspirin may reduce the risk of colon polyps and colon cancers. Giving atorvastatin and aspirin may work better at reducing the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.
Participants in this study will be divided into two groups based on their prior history of polyps/cancer. Both the researchers and the participants will know about the treatment being administered to each group.
At entry to the study, all participants will undergo a colonoscopy and biopsy of normal tissue.
After 6 weeks of taking prescribed drugs, study participants will undergo a second colonoscopy and biopsy of normal tissue.
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Contact: Yana Chertock, MA by phone: 215-214-3216 or by email
Contact: Michael Hall, MD, MS by phone: 215-728-2791 or by email
Men and women between ages 18 years to 75 years can be considered for enrollment in this study if they have:
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.